Valproic acid inhibits tumor angiogenesis in mice transplanted with Kasumi‑1 leukemia cells

Zhang,Zhi‑Hua; Hao,Chang‑Lai; Liu,Peng; Tian,Xia; Wang,Li‑Hong; Zhao,Lei; Zhu,Cui‑Min

doi:10.3892/mmr.2013.1834

Valproic acid inhibits tumor angiogenesis in mice transplanted with Kasumi‑1 leukemia cells

Authors:
- Zhi‑Hua Zhang
- Chang‑Lai Hao
- Peng Liu
- Xia Tian
- Li‑Hong Wang
- Lei Zhao
- Cui‑Min Zhu
View Affiliations

Affiliations: Affiliated Hospital of Chengde Medical College, Chengde, Hebei 067000, P.R. China, The First Hospital of Shijiazhuang City, Shijiazhuang, Hebei 050000, P.R. China, Chinese PLA 89 Hospital, Weifang, Shandong 261000, P.R. China
Published online on: November 28, 2013 https://doi.org/10.3892/mmr.2013.1834
Pages: 443-449
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Histone deacetylase (HDAC) inhibitors have been reported to inhibit tumor angiogenesis via the downregulation of angiogenic factors. Our previous in vitro studies demonstrated that valproic acid (VPA) exerted antitumor effects on Kasumi‑1 cells, which are human acute myeloid leukemia cells with an 8;21 chromosome translocation. In the present study, the effects of VPA on tumor angiogenesis were investigated in mice transplanted with Kasumi‑1 cells. Semi‑quantitative reverse transcription‑polymerase chain reaction, western blotting and immunohistochemistry were used to detect the expression of vascular endothelial growth factor (VEGF), VEGF receptor (VEGFR2) and basic fibroblast growth factor (bFGF). The tumor microvessel density was measured following staining with an anti‑CD34 antibody. Chromatin immunoprecipitation was used to study the effect of VPA‑induced histone hyperacetylation on VEGF transcription. An intraperitoneal injection of VPA inhibited tumor growth and angiogenesis in mice transplanted with Kasumi‑1 cells. The mRNA and protein expression of VEGF, VEGFR2 and bFGF were inhibited by VPA treatment. In addition, VPA downregulated HDAC, increased histone H3 acetylation and enhanced the accumulation of hyperacetylated histone H3 on the VEGF promoters. The findings of the present study indicate that VPA, an HDAC inhibitor, exerts an antileukemic effect through an anti‑angiogenesis mechanism. In conclusion, the mechanism underlying VPA‑induced anti‑angiogenesis is associated with the suppression of angiogenic factors and their receptors. VPA may increase the accumulation of acetylated histones on the VEGF promoters, which possibly contributes to the regulation of angiogenic factors.

View Figures

View References

1	Wichmann C, Chen L, Heinrich M, et al: Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells. Cancer Res. 67:2280–2289. 2007. View Article : Google Scholar : PubMed/NCBI
2	Minucci S, Nervi C, Lo Coco F and Pelicci PG: Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene. 20:3110–3115. 2001. View Article : Google Scholar : PubMed/NCBI
3	Gelmetti V, Zhang J, Fanelli M, Minucci S, Pelicci PG and Lazar MA: Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol. 18:7185–7191. 1998.PubMed/NCBI
4	Hug BA and Lazar MA: ETO interacting proteins. Oncogene. 23:4270–4274. 2004. View Article : Google Scholar : PubMed/NCBI
5	Le XF, Claxton D, Kornblau S, Fan YH, Mu ZM and Chang KS: Characterization of the ETO and AML1-ETO proteins involved in 8;21 translocation in acute myelogenous leukemia. Eur J Haematol. 60:217–225. 1998.PubMed/NCBI
6	Lutterbach B, Westendorf JJ, Linggi B, et al: ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol Cell Biol. 18:7176–7184. 1998.PubMed/NCBI
7	Marks PA, Richon VM and Rifkind RA: Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst. 92:1210–1216. 2000. View Article : Google Scholar : PubMed/NCBI
8	Redner RL, Wang J and Liu JM: Chromatin remodeling and leukemia: new therapeutic paradigms. Blood. 94:417–428. 1999.PubMed/NCBI
9	Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT and De Bruijn EA: Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 56:549–580. 2004. View Article : Google Scholar : PubMed/NCBI
10	Nussenbaum F and Herman IM: Tumor angiogenesis: insights and innovations. J Oncol. 2010:1326412010. View Article : Google Scholar : PubMed/NCBI
11	Sasakawa Y, Naoe Y, Noto T, et al: Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors. Biochem Pharmacol. 66:897–906. 2003. View Article : Google Scholar : PubMed/NCBI
12	Göttlicher M, Minucci S, Zhu P, et al: Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 20:6969–6978. 2001.
13	Zhao L, Zhang ZH and Zhu CM: Inhibitory effect of valproic acid on cell cycle of Kasumi-1 cell line and its mechanism. Zhonghua Xue Ye Xue Za Zhi. 29:802–805. 2008.(In Chinese).
14	Zhu CM, Zhang ZH, Jiang FY, et al: Effects of histone deacetylase inhibitor on the expression of angiogenesis related factors in Kasumi-1 leukemic cell line. Zhonghua Xue Ye Xue Za Zhi. 31:466–469. 2010.(In Chinese).
15	Poon RT, Ng IO, Lau C, et al: Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J Clin Oncol. 20:1775–1785. 2002. View Article : Google Scholar : PubMed/NCBI
16	Weidner N: Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol. 147:9–19. 1995.PubMed/NCBI
17	Larizza L, Magnani I and Beghini A: The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia. Leuk Lymphoma. 46:247–255. 2005. View Article : Google Scholar : PubMed/NCBI
18	Liu S, Klisovic RB, Vukosavljevic T, et al: Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells. J Pharmacol Exp Ther. 321:953–960. 2007. View Article : Google Scholar
19	Hiramatsu A, Miwa H, Shikami M, et al: Disease-specific expression of VEGF and its receptors in AML cells: possible autocrine pathway of VEGF/type1 receptor of VEGF in t(15;17) AML and VEGF/type2 receptor of VEGF in t(8;21) AML. Leuk Lymphoma. 47:89–95. 2006. View Article : Google Scholar : PubMed/NCBI
20	Imai N, Shikami M, Miwa H, et al: t(8;21) acute myeloid leukaemia cells are dependent on vascular endothelial growth factor (VEGF)/VEGF receptor type2 pathway and phosphorylation of Akt. Br J Haematol. 135:673–682. 2006. View Article : Google Scholar : PubMed/NCBI
21	Mühlethaler-Mottet A, Meier R, Flahaut M, et al: Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells. Mol Cancer. 7:552008.
22	Yang QC, Zeng BF, Shi ZM, et al: Inhibition of hypoxia-induced angiogenesis by trichostatin A via suppression of HIF-1a activity in human osteosarcoma. J Exp Clin Cancer Res. 25:593–599. 2006.PubMed/NCBI
23	Mie Lee Y, Kim SH, Kim HS, et al: Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity. Biochem Biophys Res Commun. 300:241–246. 2003.PubMed/NCBI
24	Williams RJ: Trichostatin A, an inhibitor of histone deacetylase, inhibits hypoxia-induced angiogenesis. Expert Opin Investig Drugs. 10:1571–1573. 2001. View Article : Google Scholar : PubMed/NCBI
25	Kim MS, Kwon HJ, Lee YM, et al: Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med. 7:437–443. 2001. View Article : Google Scholar : PubMed/NCBI
26	Tovar-Castillo LE, Cancino-Díaz JC, García-Vázquez F, et al: Under-expression of VHL and over-expression of HDAC-1, HIF-1alpha, LL-37, and IAP-2 in affected skin biopsies of patients with psoriasis. Int J Dermatol. 46:239–246. 2007. View Article : Google Scholar : PubMed/NCBI
27	Ellis L, Hammers H and Pili R: Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett. 280:145–153. 2009. View Article : Google Scholar : PubMed/NCBI
28	Strahl BD and Allis CD: The language of covalent histone modifications. Nature. 403:41–45. 2000. View Article : Google Scholar : PubMed/NCBI
29	Grunstein M: Histone acetylation in chromatin structure and transcription. Nature. 389:349–352. 1997. View Article : Google Scholar : PubMed/NCBI